Company Overview

Update
Founded:
1985
Headquarters:
Thousand Oaks, CA
IPO:
Went Public on Jan 24, 1983
Stock:
AMGN
Categories:
Biotechnology
Description:
Amgen engages in the development of human therapeutic products in supportive of cancer care, inflammation, nephrology and bone diseases.

Detailed Description

Update

Amgen Inc. - The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation.

The Group's key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis.

Current Team (21)

Update

Past Team (106)

Update
  • B4333b773971949f1a7991b47f480ca0

    Stuart A. Arbuckle

    Vice President and Regional General Manager sia, the Middle East and Africa
  • B4333b773971949f1a7991b47f480ca0

    Stuart A. Arbuckle

    Vice President and General Manager, Oncology Business Unit
  • 3ad17a7b0392a5d9e2d2fd033b7fa817

    Robert A. Bradway

    President and Chief Operating Officer ,, Board of Directors,,Vice President, Operations Strategy ,,Executive Vice President and Chief Financial Officer
  • E4e12a24e3bb2e89b69aa68da21ad045

    Jorge Amaro

    Various Positions
  • 881ad09818be561fe7e4a5c7c3e6e2f6

    L. Arthur Hewitt

    Head of Clinical Research and Regulatory Affairs in Canada
  • 1913ce3745a5bebb045ad50c73e71757

    Philip Astley-Sparke

    VP / General Manager
    Mar, 2011 - Dec, 2011
  • 6e7c72c54a9fbabbd857eca79da097c7

    Madhavan Balachandran

    Senior Vice President, Manufacturing, Responsible for Operations ,, Vice President, Information Management, and Director, Engineering Operations Services
  • 901455353e6e99effabbad88fc131f9a

    Luis Bayol

    Director of Operations

Funding Rounds (1) - $175.5M

Update

Investments (30)

Update

Board Members and Advisors (12)

Update

Acquisitions (6)

Update

Offices/Locations (1)

Update
  • HQ

    One Amgen Center Drive

    Thousand Oaks, CA 91320-1799

    USA

Images (2)

Update
  • F4129afa803a47dd30deba939586a065
  • Bd93908fed262cfc4612a92c8bc93f6a